Thymosin β4 and BPC-157 as Candidate Regenerative Peptide Therapies for Spinal Cord Injury: Mechanisms, Preclinical Evidence, and First Clinical Signals

Spinal cord injury (SCI) remains without an approved pharmacological therapy capable of restoring lost neurological function, and recovery in motor-complete, sensory-incomplete (AIS B) patients is constrained by a limited spontaneous-conversion profile. Two regenerative peptides have assembled convergent preclinical rationales in SCI. Thymosin β4 (Tβ4), the principal G-actin-sequestering peptide of eukaryotic cells, promotes oligodendrogenesis, axonal remodeling, angiogenesis, and anti-inflammatory signalling, and has improved functional recovery in rodent SCI. The stable gastric pentadecapeptide BPC-157 acts chiefly through VEGFR2 upregulation and the Akt–eNOS nitric-oxide axis, and has produced consistent functional recovery in rat SCI models. This review synthesises the molecular pharmacology of both agents, the preclinical SCI literature, the limited human exposure data, and the safety and regulatory context, including the important distinction between full-length Tβ4 and the synthetic fragment TB-500. It then examines the first clinical signal: a 6-month open-label controlled pilot in subacute AIS-B thoracic SCI in which weekly subcutaneous Tβ4 plus BPC-157, added to intensive rehabilitation, was associated with larger motor, sensory, trunk, and autonomic gains than rehabilitation alone, with only mild adverse effects. The evidence base remains preclinical-first and hypothesis-generating; the design requirements for a confirmatory trial are outlined. Neither peptide is approved for SCI, and both are subject to significant regulatory restrictions.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-16
DOI
https://doi.org/10.20944/preprints202611.1567.v1
Primary Topic
Spinal Cord Injury Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Thymosin β4 and BPC-157 as Candidate Regenerative Peptide Therapies for Spinal Cord Injury: Mechanisms, Preclinical Evidence, and First Clinical Signals

Pritam Majumdar, Ulduz Jafarova, Igor Aleksandrovich Lavrov, Georgios Matis et al.
Preprints.org
Spinal Cord Injury Research
preprint

Thymosin β4 and BPC-157 as Candidate Regenerative Peptide Therapies for Spinal Cord Injury: Mechanisms, Preclinical Evidence, and First Clinical Signals

Pritam Majumdar, Ulduz Jafarova, Igor Aleksandrovich Lavrov, Georgios Matis, Monzurul Alam, Surbhi Kaura
preprint en

Abstract

Spinal cord injury (SCI) remains without an approved pharmacological therapy capable of restoring lost neurological function, and recovery in motor-complete, sensory-incomplete (AIS B) patients is constrained by a limited spontaneous-conversion profile. Two regenerative peptides have assembled convergent preclinical rationales in SCI. Thymosin β4 (Tβ4), the principal G-actin-sequestering peptide of eukaryotic cells, promotes oligodendrogenesis, axonal remodeling, angiogenesis, and anti-inflammatory signalling, and has improved functional recovery in rodent SCI. The stable gastric pentadecapeptide BPC-157 acts chiefly through VEGFR2 upregulation and the Akt–eNOS nitric-oxide axis, and has produced consistent functional recovery in rat SCI models. This review synthesises the molecular pharmacology of both agents, the preclinical SCI literature, the limited human exposure data, and the safety and regulatory context, including the important distinction between full-length Tβ4 and the synthetic fragment TB-500. It then examines the first clinical signal: a 6-month open-label controlled pilot in subacute AIS-B thoracic SCI in which weekly subcutaneous Tβ4 plus BPC-157, added to intensive rehabilitation, was associated with larger motor, sensory, trunk, and autonomic gains than rehabilitation alone, with only mild adverse effects. The evidence base remains preclinical-first and hypothesis-generating; the design requirements for a confirmatory trial are outlined. Neither peptide is approved for SCI, and both are subject to significant regulatory restrictions.

Preprints.org
Spinal Cord Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon